Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02600949 · ClinicalTrials.gov registry record · Phase 1

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

A Phase 1 study of Metastatic Pancreatic Ductal Adenocarcinoma and Metastatic Colorectal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 1
Development phase
117
Enrollment target
1
Study location

NCT02600949 is a Phase 1 study of Metastatic Pancreatic Ductal Adenocarcinoma and Metastatic Colorectal Adenocarcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 117 participants, below the 179-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02600949, a Phase 1 study of Metastatic Pancreatic Ductal Adenocarcinoma and Metastatic Colorectal Adenocarcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
117 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing or kill them.

Conditions Studied

Metastatic Pancreatic Ductal Adenocarcinoma Metastatic Colorectal Adenocarcinoma Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IV Colorectal Cancer AJCC v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7

Interventions

  • BIOLOGICAL Pembrolizumab
  • PROCEDURE Computed Tomography
  • DRUG Imiquimod
  • BIOLOGICAL Sotigalimab
  • BIOLOGICAL Synthetic Tumor-Associated Peptide Vaccine Therapy

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2016-05-11
Est. Completion 2027-05-31
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02600949

The ClinicalTrials.gov registry entry for NCT02600949 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 20 other Metastatic Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (35% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Metastatic Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT02600949 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02600949 about?

NCT02600949 is a clinical study titled "Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer". This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine de...

What is the current status of trial NCT02600949?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2016-05-11. Estimated completion is 2027-05-31.

What conditions does trial NCT02600949 study?

This clinical trial studies the following conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7.

What interventions are being tested in trial NCT02600949?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Computed Tomography (PROCEDURE), Imiquimod (DRUG), Sotigalimab (BIOLOGICAL), Synthetic Tumor-Associated Peptide Vaccine Therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT02600949?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02600949 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Pancreatic Ductal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

Metastatic Colorectal Adenocarcinoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.